Kymeta Announces S. Douglas Hutcheson as Executive Chairman, Board of Directors, and Walter Z. Berger as President, CFO, and COO
Kymeta—the communications company that is completing the connectivity fabric for everything, everywhere—announced that S. Douglas Hutcheson is joining the Kymeta Board of Directors and will be named Executive Chairman and Walter Z. Berger has been hired as President, Chief Financial Officer (CFO), and Chief Operating Officer (COO).
Hutcheson serves as Senior Advisor of Technology, Media and Telecom for Searchlight Capital and on several boards, both public and private. Previously, as CEO of Leap Wireless for nearly a decade, he oversaw the company’s operations and managed its eventual sale to AT&T. He brings extensive telecommunications and technology experience, having held several senior leadership positions at Leap after serving as an executive with Qualcomm.
“Kymeta is leading the industry in hybrid communication solutions, and I’m excited to come on board as Executive Chairman,” said Doug Hutcheson, Kymeta Executive Chairman. “The telecommunications industry has made major strides over the last 25 years, and I believe Kymeta is well positioned to deliver on the promise of mobile connectivity around the world.”
Berger most recently served as COO and CFO of Nuvectra, a neuromodulation medical device platform company. Before joining Nuvectra, he served in senior executive positions at AppDynamics, a next-generation application intelligence company, which was acquired by Cisco. He also held senior executive positions at SoftLayer, a cloud computing company, which was acquired by IBM, and Leap Wireless. Additionally, he has held several executive operating, financial, and general leadership roles in various industry verticals and brings extensive experience as a senior business leader ranging from Fortune 500 companies to private equity and venture capital invested companies. He has also served on multiple for-profit and non-profit boards.
“Kymeta is connecting the world with hybrid telecommunications systems,” said Walter Berger, Kymeta President, CFO, COO. “I’m thrilled to be joining this dynamic organization at a time when there is so much opportunity for growth.”
Hutcheson and Berger join Kymeta at a pivotal time for the company. “We couldn’t be happier to bring Doug and Walter on board,” said Rodi Guidero, Director and outgoing Chairman, Kymeta Board of Directors. “They both bring valuable experience and perspective that will launch Kymeta into its next phase of growth.”
About Kymeta
Kymeta is unlocking the potential of satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for global ubiquitous mobile connectivity. The company’s flat-panel satellite antenna, the first of its kind, and Kymeta KĀLO™ connectivity services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190521005291/en/
Contact information
Business Inquiries for Kymeta:
Sam Christensen
Head of
Marketing and Communications
Kymeta Corporation
+1 425.658.8703
schristensen@kymetacorp.com
Media Inquiries for Kymeta:
Melanie McBride
Vice
President, Content and PR
The Summit Group
+1 801.990.8464
mmcbride@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release
KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 11:17:00 EEST | Press release
Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom